clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ammon S et al. | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848660 |
Leiper K et al. | Open label trial of oral clarithromycin in active Crohn's disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848665 |
Sharara AI et al. | Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. | 2015 | Aliment. Pharmacol. Ther. | pmid:26238584 |
Graham DY and Gisbert JP | Letter: clarithromycin dose for H. pylori therapy remains unresolved. | 2015 | Aliment. Pharmacol. Ther. | pmid:26238583 |
Van Oijen AH et al. | Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930892 |
Hurenkamp GJ et al. | Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930901 |
Kositchaiwat C et al. | Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:14616168 |
Wheeldon TU et al. | Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848630 |
Romero-Gómez M et al. | Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. | 2003 | Aliment. Pharmacol. Ther. | pmid:14616169 |
Datta S et al. | Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963080 |
Dalla Libera M et al. | High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. | 1996 | Aliment. Pharmacol. Ther. | pmid:8730251 |
Labenz J et al. | One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8730252 |
Cardenas VM et al. | Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. | 2006 | Aliment. Pharmacol. Ther. | pmid:16393310 |
Gatta L et al. | A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963079 |
Murakami K et al. | Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. | 2002 | Aliment. Pharmacol. Ther. | pmid:12390102 |
Wong BC et al. | Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. | 2001 | Aliment. Pharmacol. Ther. | pmid:11380322 |
Lamouliatte H et al. | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535872 |
Gisbert JP and Calvet X | Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. | 2012 | Aliment. Pharmacol. Ther. | pmid:22129228 |
Miehlke S et al. | Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535873 |
Bühling A et al. | Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552917 |
Neri M et al. | Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535876 |
Hokari K et al. | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552922 |
Dani R et al. | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594400 |
Lai KC et al. | Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535877 |
Kamberoglou D et al. | Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552924 |
Harris A | The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594406 |
al-Assi MT et al. | Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:7986970 |
Neri M et al. | Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:7986974 |
Okudaira K et al. | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. | 2005 | Aliment. Pharmacol. Ther. | pmid:15710002 |
Lai KC et al. | Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:12641502 |
Zullo A et al. | High eradication rates of Helicobacter pylori with a new sequential treatment. | 2003 | Aliment. Pharmacol. Ther. | pmid:12641522 |
Lehmann FS et al. | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735923 |
Miwa H et al. | Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735925 |
Spinzi GC et al. | Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735926 |
Graham DY et al. | Furazolidone combination therapies for Helicobacter pylori infection in the United States. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651662 |
Wong BC et al. | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651663 |
Lane JA et al. | Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. | 2011 | Aliment. Pharmacol. Ther. | pmid:21366634 |
Fock KM et al. | Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651664 |
Lamouliatte H et al. | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10571611 |
Harris AW et al. | Eradication of Helicobacter pylori with lansoprazole and clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605863 |
Katelaris PH et al. | A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605864 |
Yousfi MM et al. | Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605865 |
Malfertheiner P et al. | Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969088 |
Hassan C et al. | Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969091 |
Sheu BS et al. | Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856088 |
Choi IJ et al. | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856089 |
Bazzoli F et al. | Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856090 |
Kim JS et al. | Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860410 |
Malfertheiner P et al. | Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860399 |
Barth J and Hahne W | Review article: rabeprazole-based therapy in Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849125 |
Miwa H et al. | Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383502 |
Qasim A and O'Morain CA | Review article: treatment of Helicobacter pylori infection and factors influencing eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849124 |
Ducóns JA et al. | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383507 |
Calvet X et al. | Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383508 |
Sieg A et al. | Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383519 |
Cestari R | Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798804 |
Grimley CE et al. | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383520 |
Spadaccini A et al. | Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798805 |
Houben MH et al. | Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383522 |
Bortolotti M et al. | Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798808 |
Vakil N et al. | Seven-day therapy for Helicobacter pylori in the United States. | 2004 | Aliment. Pharmacol. Ther. | pmid:15225176 |
Gisbert JP and Calvet X | Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. | 2011 | Aliment. Pharmacol. Ther. | pmid:21745241 |
John Albert M et al. | High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. | 2006 | Aliment. Pharmacol. Ther. | pmid:17059517 |
Villoria A et al. | Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. | 2008 | Aliment. Pharmacol. Ther. | pmid:18644011 |
Furuta T et al. | Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. | 2007 | Aliment. Pharmacol. Ther. | pmid:17697203 |
Veldhuyzen Van Zanten S et al. | One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121908 |
Isomoto H et al. | 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121910 |
Canducci F et al. | A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121911 |
Kim YS et al. | Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. | 2011 | Aliment. Pharmacol. Ther. | pmid:21923713 |
Leiper K et al. | Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. | 2008 | Aliment. Pharmacol. Ther. | pmid:18315579 |
Spadaccini A et al. | Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers. | 1996 | Aliment. Pharmacol. Ther. | pmid:8899094 |
Thung I et al. | Review article: the global emergence of Helicobacter pylori antibiotic resistance. | 2016 | Aliment. Pharmacol. Ther. | pmid:26694080 |
Dobrilla G et al. | Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692703 |
Kawabata H et al. | Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. | 2003 | Aliment. Pharmacol. Ther. | pmid:12534411 |
Gisbert JP et al. | Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:11012477 |
Catalano F et al. | Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. | 2000 | Aliment. Pharmacol. Ther. | pmid:11012478 |
Gomollón F et al. | Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. | 2000 | Aliment. Pharmacol. Ther. | pmid:11012479 |
Ford AC et al. | Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. | 2007 | Aliment. Pharmacol. Ther. | pmid:17944741 |
Graham DY et al. | Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102946 |
Zanten SJ et al. | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102960 |
Van der Wouden EJ et al. | The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102961 |
Wong BC et al. | Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102962 |
Nista EC et al. | Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969089 |
Savarino V et al. | A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. | 1997 | Aliment. Pharmacol. Ther. | pmid:9305478 |
Williams MP et al. | Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. | 1997 | Aliment. Pharmacol. Ther. | pmid:9305479 |
Janssen MJ et al. | A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. | 2001 | Aliment. Pharmacol. Ther. | pmid:11328254 |
Tankovic J et al. | Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. | 2001 | Aliment. Pharmacol. Ther. | pmid:11328266 |
Broutet N et al. | Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492738 |
Higuchi K et al. | Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492739 |
Coelho LG et al. | Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492742 |
Ott EA et al. | Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882244 |
Feydt-Schmidt A et al. | Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. | 2002 | Aliment. Pharmacol. Ther. | pmid:12452940 |
Isomoto H et al. | High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848631 |
Zullo A et al. | Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. | 2007 | Aliment. Pharmacol. Ther. | pmid:17539982 |
Nista EC et al. | Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. | 2004 | Aliment. Pharmacol. Ther. | pmid:15569121 |
Chen PY et al. | Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074519 |
Zamani M et al. | Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074507 |
Laine L and Dhir V | Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030957 |
Vallve M et al. | Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030958 |
Colin R | Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030959 |